{"id":38591,"date":"2017-04-17T06:41:12","date_gmt":"2017-04-17T10:41:12","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=38591"},"modified":"2017-04-17T05:42:12","modified_gmt":"2017-04-17T09:42:12","slug":"the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591","title":{"rendered":"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain"},"content":{"rendered":"<p style=\"text-align: justify;\">The recent turn of events in some of the top stocks have raised eyebrows worldwide, but what <strong>Eli Lilly and Co (NYSE:LLY) <\/strong>and<strong> Incyte Corporation (NASDAQ:INCY) <\/strong>have become the highest talk cutting through the air!<\/p>\n<p style=\"text-align: justify;\">The two chose Friday, which as a matter of fact happens to be a market holiday to actually disclose the fact that FDA had frustrated their efforts after it openly rejected their rheumatoid arthritis pill baricitinib.<\/p>\n<p style=\"text-align: justify;\">\u00a0This was indeed a major blur considering the much time and effort they had redirected towards coming up with the pill. However, anyone can quite easily agree that not every day is a good day for business. There is still room for improvement for the two top-notch providers!<\/p>\n<p style=\"text-align: justify;\">Monday is the day! Yes you got it right. It is the exact day when the repercussions from the regulatory setback that impacted the stocks in such a negative way will be announced publicly. Speculations will as a matter of fact rent the air over the future of the two trusted providers, but let\u2019s face it, only time will tell.<\/p>\n<p style=\"text-align: justify;\">According to a number of the top sources, there were indeed high expectations that Baricitinib would most probably secure U.S approval and still move ahead to deliver about $2 billion or more in peak sales and it is worth mentioning that it was believed to be a very effective remedy in dealing with the oral JAK inhibitor for rheumatoid arthritis was to become the next big thing after <strong>Pfizer Inc (NYSE:PFE)\u2019s <\/strong>Xeljanz.<\/p>\n<p style=\"text-align: justify;\">Some indefinite hold has been put on the plans at the moment and it is a call for alarm for a lot of the investors associated with the providers.<\/p>\n<p style=\"text-align: justify;\">As anyone would have expected for things to turn out, the two business giants seriously disagreed with FDA\u2019s conclusions and the plan to move ahead and resubmit baricitinib for another shot in order to try their luck on the approval of the product.<\/p>\n<p style=\"text-align: justify;\">According to trusted sources, the exact timeline for this particular resubmission was not clearly stipulated. Anyone can speculate anything regarding what the future unveils as a matter of fact, but what matters is the real truth and that will of course come out clearly with the passage of time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The recent turn of events in some of the top stocks have raised eyebrows worldwide, but what Eli Lilly and Co (NYSE:LLY) and Incyte Corporation [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":38597,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7031,5208,3230,1736,1737,1769,993,2745,3275],"stock_ticker":[],"class_list":["post-38591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-eli-lilly-and-co","tag-eli-lilly-and-co-nyselly","tag-incyte-corporation","tag-incyte-corporation-nasdaqincy","tag-nasdaqincy","tag-nyselly","tag-nysepfe","tag-pfizer-inc-nysepfe","tag-pfizer-inc","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The recent turn of events in some of the top stocks have raised eyebrows worldwide, but what Eli Lilly and Co (NYSE:LLY) and Incyte Corporation [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-17T10:41:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"275\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain\",\"datePublished\":\"2017-04-17T10:41:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg\",\"keywords\":[\"Eli Lilly and Co\",\"Eli Lilly and Co (NYSE:LLY)\",\"Incyte Corporation\",\"Incyte Corporation (NASDAQ:INCY\",\"NASDAQ:INCY\",\"NYSE:LLY\",\"NYSE:PFE\",\"Pfizer Inc (NYSE:PFE)\",\"Pfizer Inc.\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\",\"name\":\"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg\",\"datePublished\":\"2017-04-17T10:41:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg\",\"width\":275,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591","og_locale":"en_US","og_type":"article","og_title":"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain - Wall Street PR","og_description":"The recent turn of events in some of the top stocks have raised eyebrows worldwide, but what Eli Lilly and Co (NYSE:LLY) and Incyte Corporation [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-04-17T10:41:12+00:00","og_image":[{"width":275,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain","datePublished":"2017-04-17T10:41:12+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg","keywords":["Eli Lilly and Co","Eli Lilly and Co (NYSE:LLY)","Incyte Corporation","Incyte Corporation (NASDAQ:INCY","NASDAQ:INCY","NYSE:LLY","NYSE:PFE","Pfizer Inc (NYSE:PFE)","Pfizer Inc."],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591","url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591","name":"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg","datePublished":"2017-04-17T10:41:12+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/04\/38596-images__9_.jpeg","width":275,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-incyte-rheumatoid-arthritis-pill-setback-poses-disagreements-with-fda-as-pfizer-inc-nysepfe-and-others-stand-to-gain-38591#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/38591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=38591"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/38591\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/38597"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=38591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=38591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=38591"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=38591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}